STAT3 and prostate carcinoma: In localized and metastatic castration-resistant prostate cancer patients, treatment with TLR9-targeted STAT3 siRNA delivery to abrogate the immunosuppressive function of MDSCs diminished the enzymatic activity of Arg-1, inhibited STAT3 target gene and T cell function (Hossain et al., 2015).